Journal of Traditional Chinese Medicine ›› 2021, Vol. 41 ›› Issue (2): 308-315.DOI: 10.19852/j.cnki.jtcm.2021.02.009

Previous Articles     Next Articles

Clinical observation of Yiqi Qingdu Prescription(益气清毒方)on the treatment of intermediate-stage and advanced non-small-cell lung cancer

LIANG Qijun;TANG Xiaoling;YU Jiong;XIONG Monian;ZHU Huifang;XIONG Linkai;ZENG Ru;YU Peiwen;   

  1. [Liang Qijun] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Dept Resp, Nanchang 330006, Jiangxi, Peoples R China; [Tang Xiaoling] Jiangxi Inst Tradit Chinese Med, Affiliated Hosp, Dept Oncol, Nanchang 330046, Jiangxi, Peoples R China; [Yu Jiong; Xiong Monian] Jiangxi Inst Tradit Chinese Med, Key Lab Yiqi Qingdu Malignant Tumor, Nanchang 330046, Jiangxi, Peoples R China; [Zhu Huifang; Zeng Ru; Yu Peiwen] Jiangxi Univ Tradit Chinese Med, Sch Clin Med, Nanchang 330004, Jiangxi, Peoples R China; [Xiong Linkai] Jiangxi Tumor Hosp, Dept Internal Med 2, Nanchang 330029, Jiangxi, Peoples R China
  • Online:2021-04-15 Published:2021-04-15
  • Supported by:
    Supported by Xiong Monian National Famous and Senior Chinese Medicine Experts Inheritance Studio Construction Project (No. 47 [2013], the Personnel and Education Department of the State Administration of Traditional Chinese Medicine promulgated);; Key R&D projects in Jiangxi Province:lung cancer prevention and treatment,health preservation technology and products based on the method of"Tonifying Qi and Cleaning Toxin"(No. 20171BBG70113)

Abstract: OBJECTIVE:To observe the effects of the Yiqi Qingdu prescription(益气清毒方)on intermediate-stage and advanced non-small-cell lung cancer(NSCLC).METHODS:In total,300 patients with intermediate-stage or advanced NSCLC were randomly and equally divided into three groups using computer-generated random numbers as follows:Western medicine(WM),Chinese medicine(CM),and integrated Traditional Chinese and Western Medicine(IM).After 3 months of treatment,the overall response rate(ORR);disease control rate(DCR);symptom score(SS);Karnofsky performance status(KPS);adverse event score;counts of CD3~+,CD4~+,and CD8~+ cells;CD4~+/CD8~+ ratio;and carcinoembryonic antigen(CEA) level were compared among the groups.RESULTS:The ORRs were 30.36%, 20.24%, and7.87% in the IM,CM,and WM groups,respectively,whereas the DCRs were 85%,75%,and 73%,respectively.Compared to the CM group,the ORR was significantly higher in the WM and IM groups,whereas the DCR was significantly higher in the IM group(all P

Key words: carcinoma,non-small-cell lung;;integrative medicine;;therapeutic uses;;carcinoembryonic antigen;;antigens,differentiation,T-lymphocyte;;Yiqi Qingdu prescription

Cite this article

LIANG Qijun;TANG Xiaoling;YU Jiong;XIONG Monian;ZHU Huifang;XIONG Linkai;ZENG Ru;YU Peiwen;. Clinical observation of Yiqi Qingdu Prescription(益气清毒方)on the treatment of intermediate-stage and advanced non-small-cell lung cancer[J]. Journal of Traditional Chinese Medicine, 2021, 41(2): 308-315.